BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 6.31% at $142.50 after the company announced its Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response against the Omicron variant.
Pfizer Inc. (NYSE:PFE) and BioNTech said data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies' current COVID-19 vaccine. The robust immune response was seen across two investigational dose levels, 30 µg and 60 µg.
See Also: Why Axsome Therapeutics Stock Is Soaring Today
BioNTech is a Germany-based biotechnology company.
According to data from Benzinga Pro, BioNTech has a 52-week high of $464.00 and a 52-week low of $117.08.
